|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Williams C and Lin CY: Oestrogen receptors
in breast cancer: basic mechanisms and clinical implications.
Ecancermedicalscience. 7:3702013.PubMed/NCBI
|
|
3
|
Fisher B, Costantino JP, Wickerham DL, et
al: Tamoxifen for prevention of breast cancer: report of the
National Surgical Adjuvant Breast and Bowel Project P-1 Study. J
Natl Cancer Inst. 90:1371–1388. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogel VG, Costantino JP, Wickerham DL, et
al: Effects of tamoxifen vs raloxifene on the risk of developing
invasive breast cancer and other disease outcomes: the NSABP Study
of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 295:2727–2741.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baqai T and Shousha S: Oestrogen receptor
negativity as a marker for high-grade ductal carcinoma in situ of
the breast. Histopathology. 42:440–447. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Provenzano E, Hopper JL, Giles GG, Marr G,
Venter DJ and Armes JE: Biological markers that predict clinical
recurrence in ductal carcinoma in situ of the breast. Eur J Cancer.
39:622–630. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Istvan ES and Deisenhofer J: Structural
mechanism for statin inhibition of HMG-CoA reductase. Science.
292:1160–1164. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang FL and Casey PJ: Protein
prenylation: molecular mechanisms and functional consequences. Annu
Rev Biochem. 65:241–269. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jackson SM, Ericsson J and Edwards PA:
Signaling molecules derived from the cholesterol biosynthetic
pathway. Subcell Biochem. 28:1–21. 1997.PubMed/NCBI
|
|
10
|
Hebert PR, Gaziano JM, Chan KS and
Hennekens CH: Cholesterol lowering with statin drugs, risk of
stroke, and total mortality. An overview of randomized trials.
JAMA. 278:313–321. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kochuparambil ST, Al-Husein B, Goc A,
Soliman S and Somanath PR: Anticancer efficacy of simvastatin on
prostate cancer cells and tumor xenografts is associated with
inhibition of Akt and reduced prostate-specific antigen expression.
J Pharmacol Exp Ther. 336:496–505. 2011. View Article : Google Scholar
|
|
12
|
Ghosh-Choudhury N, Mandal CC, Ghosh
Choudhury N and Ghosh Choudhury G: Simvastatin induces derepression
of PTEN expression via NFkappaB to inhibit breast cancer cell
growth. Cell Signal. 22:749–758. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sassano A and Platanias LC: Statins in
tumor suppression. Cancer Lett. 260:11–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pelaia G, Gallelli L, Renda T, et al:
Effects of statins and farnesyl transferase inhibitors on ERK
phosphorylation, apoptosis and cell viability in non-small lung
cancer cells. Cell Prolif. 45:557–565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Relja B, Meder F, Wilhelm K, Henrich D,
Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces
apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int
J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahern TP, Pedersen L, Tarp M, et al:
Statin prescriptions and breast cancer recurrence risk: a Danish
nationwide prospective cohort study. J Natl Cancer Inst.
103:1461–1468. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kumar AS, Benz CC, Shim V, Minami CA,
Moore DH and Esserman LJ: Estrogen receptor-negative breast cancer
is less likely to arise among lipophilic statin users. Cancer
Epidemiol Biomarkers Prev. 17:1028–1033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bonovas S, Filioussi K, Tsavaris N and
Sitaras NM: Use of statins and breast cancer: a meta-analysis of
seven randomized clinical trials and nine observational studies. J
Clin Oncol. 23:8606–8612. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Riemsma R, Forbes CA, Kessels A, et al:
Systematic review of aromatase inhibitors in the first-line
treatment for hormone sensitive advanced or metastatic breast
cancer. Breast Cancer Res Treat. 123:9–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mork CN, Faller DV and Spanjaard RA: A
mechanistic approach to anticancer therapy: targeting the cell
cycle with histone deacetylase inhibitors. Curr Pharm Des.
11:1091–1104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meeran SM and Katiyar SK: Cell cycle
control as a basis for cancer chemoprevention through dietary
agents. Front Biosci. 13:2191–2202. 2008. View Article : Google Scholar :
|
|
24
|
Murray AW: Recycling the cell cycle:
cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
26
|
Pavletich NP: Mechanisms of
cyclin-dependent kinase regulation: structures of Cdks, their
cyclin activators, and Cip and INK4 inhibitors. J Mol Biol.
287:821–828. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lefranc F, Facchini V and Kiss R:
Proautophagic drugs: a novel means to combat apoptosis-resistant
cancers, with a special emphasis on glioblastomas. Oncologist.
12:1395–1403. 2007. View Article : Google Scholar
|
|
28
|
Korsmeyer SJ, Shutter JR, Veis DJ, Merry
DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an
anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332.
1993.PubMed/NCBI
|
|
29
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Renault TT and Chipuk JE: Death upon a
kiss: mitochondrial outer membrane composition and organelle
communication govern sensitivity to BAK/BAX-dependent apoptosis.
Chem Biol. 21:114–123. 2014. View Article : Google Scholar :
|
|
31
|
Fang Y, Elahi A, Denley RC, Rao PH,
Brennan MF and Jhanwar SC: Molecular characterization of permanent
cell lines from primary, metastatic and recurrent malignant
peripheral nerve sheath tumors (MPNST) with underlying
neurofibro-matosis-1. Anticancer Res. 29:1255–1262. 2009.PubMed/NCBI
|
|
32
|
Boulakia CA, Chen G, Ng FW, et al: Bcl-2
and adenovirus E1B 19 kDA protein prevent E1A-induced processing of
CPP32 and cleavage of poly(ADP-ribose) polymerase. Oncogene.
12:529–535. 1996.PubMed/NCBI
|
|
33
|
Chinnaiyan AM, Orth K, O’Rourke K, Duan H,
Poirier GG and Dixit VM: Molecular ordering of the cell death
pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like
apoptotic proteases. J Biol Chem. 271:4573–4576. 1996.PubMed/NCBI
|
|
34
|
Zou H, Henzel WJ, Liu X, Lutschg A and
Wang X: Apaf-1, a human protein homologous to C. elegans CED-4,
participates in cytochrome c-dependent activation of caspase-3.
Cell. 90:405–413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dai Y, Qiao L, Chan KW, et al: Loss of
XIAP sensitizes rosiglitazone-induced growth inhibition of colon
cancer in vivo. Int J Cancer. 122:2858–2863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sasaki H, Sheng Y, Kotsuji F and Tsang BK:
Down-regulation of X-linked inhibitor of apoptosis protein induces
apoptosis in chemoresistant human ovarian cancer cells. Cancer Res.
60:5659–5666. 2000.PubMed/NCBI
|
|
37
|
Yadav L, Puri N, Rastogi V, Satpute P,
Ahmad R and Kaur G: Matrix metalloproteinases and cancer - roles in
threat and therapy. Asian Pac J Cancer Prev. 15:1085–1091. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li HC, Cao DC, Liu Y, et al: Prognostic
value of matrix metalloproteinases (MMP-2 and MMP-9) in patients
with lymph node-negative breast carcinoma. Breast Cancer Res Treat.
88:75–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin ZM, Zhao JX, Duan XN, et al: Effects
of tissue factor, PAR-2 and MMP-9 expression on human breast cancer
cell line MCF-7 invasion. Asian Pac J Cancer Prev. 15:643–646.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Izidoro-Toledo TC, Guimaraes DA, Belo VA,
Gerlach RF and Tanus-Santos JE: Effects of statins on matrix
metalloproteinases and their endogenous inhibitors in human
endothelial cells. Naunyn Schmiedebergs Arch Pharmacol.
383:547–554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fromigué O, Hamidouche Z and Marie PJ:
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces
osteosarcoma cell invasion. J Biol Chem. 283:30549–30556. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karin M and Lin A: NF-kappaB at the
crossroads of life and death. Nat Immunol. 3:221–227. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jana D, Das S, Sarkar DK, Mandal S, Maji A
and Mukhopadhyay M: Role of nuclear factor-κB in female breast
cancer: a study in Indian patients. Asian Pac J Cancer Prev.
13:5511–5515. 2012. View Article : Google Scholar
|
|
44
|
Prajoko YW and Aryandono T: Expression of
nuclear factor kappa B (NF-κB) as a predictor of poor pathologic
response to chemotherapy in patients with locally advanced breast
cancer. Asian Pac J Cancer Prev. 15:595–598. 2014. View Article : Google Scholar
|
|
45
|
Gallogly MM, Shelton MD, Qanungo S, et al:
Glutaredoxin regulates apoptosis in cardiomyocytes via NFkappaB
targets Bcl-2 and Bcl-xL: implications for cardiac aging. Antioxid
Redox Signal. 12:1339–1353. 2010. View Article : Google Scholar :
|
|
46
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar
|
|
47
|
Hu LX, Du YY, Zhang Y and Pan YY:
Synergistic effects of exemestane and aspirin on MCF-7 human breast
cancer cells. Asian Pac J Cancer Prev. 13:5903–5908. 2012.
View Article : Google Scholar
|
|
48
|
Stoehr M, Mozet C, Boehm A, Aigner A,
Dietz A and Wichmann G: Simvastatin suppresses head and neck
squamous cell carcinoma ex vivo and enhances the cytostatic effects
of chemotherapeutics. Cancer Chemother Pharmacol. 73:827–837. 2014.
View Article : Google Scholar : PubMed/NCBI
|
